2026-04-13T06:43:18Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/94272024-06-06T13:27:17Zcom_2072_378071com_2072_378040col_2072_378097

00925njm 22002777a 4500 dc Moreno, Celia author Ramos Elbal, Eduardo author Velasco Puyó, Pablo author Aguilar de la Red, Yurena author Gonzáález Martínez, Berta author Fuentes, Carolina author Díaz de Heredia Rubio, Maria Cristina author 2023-04-26T11:40:35Z 2023-04-26T11:40:35Z 2023-03-20 Acute lymphoblastic leukemia; Children; Stem cell transplantation Leucemia linfoblástica aguda; Niños; Trasplante de células madre Leucèmia limfoblàstica aguda; Nens; Trasplantament de cèl·lules mare Introduction: Studies addressing the role of haploidentical as alternative to HLA-matched donors for stem cell transplantation (SCT) often include patients with diverse hematological malignancies in different remission statuses. Methods: We compared outcomes of children with acute lymphoblastic leukemia (ALL) undergoing SCT in second complete remission (CR2) from haploidentical (n = 25) versus HLA-matched donor (n = 51). Results: Patients were equally distributed across both groups according to age, immunophenotype, time to and site of relapse, relapse risk-group allocation, and minimal residual disease (MRD) before SCT. Incidence of graft failure, acute graft versus host disease (GVHD), and other early complications did not differ between both groups. We found no differences in overall survival (58.7% versus 59.5%; p = .8), leukemia free survival (LFS) (48% versus 36.4%; p = .5), event free survival (40% versus 34.4%; p = .69), cumulative incidence (CI) of subsequent relapse (28% versus 40.9%; p = .69), treatment related mortality (24% versus 23.6%; p = .83), CI of cGVHD (4.5% versus 18.7%; p = .2), and chronic GVHD-free and leukemia-free survival (44% versus 26.3%; p = .3) after haploidentical donor SCT. Chronic GVHD (HR = 0.09; p=.02) had protective impact, and MRD ≥ 0.01% before SCT (HR = 2.59; p=.01) had unfavorable impact on LFS. Discussion: These results support the role of haploidentical donor SCT in children with ALL in CR2. Infants Cèl·lules mare hematopoètiques - Trasplantació Leucèmia limfoblàstica - Tractament ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Cell- and Tissue-Based Therapy::Cell Transplantation::Stem Cell Transplantation::Hematopoietic Stem Cell Transplantation DISEASES::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma Other subheadings::Other subheadings::/therapy NAMED GROUPS::Persons::Age Groups::Child TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::tratamientos basados en células y tejidos::trasplante de células::trasplante de células madre::trasplante de células madre hematopoyéticas ENFERMEDADES::neoplasias::neoplasias por tipo histológico::leucemia::leucemia linfoide::leucemia-linfoma linfoblástico de células precursoras Otros calificadores::Otros calificadores::/terapia DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet)